Immune Monitor - January 2022

A Message from the President

Dear Colleagues,

Welcome to 2022!

To start off the year, I am excited to share the Society for Immunotherapy of Cancer’s (SITC) first Fireside Chat on a fascinating topic, the microbiome. I was able to bring together two of the pioneers in research on this topic in past president of SITC Thomas F. Gajewski, MD, PhD, University of Chicago and Jennifer A. Wargo, MD, MMSc, The University of Texas MD Anderson Cancer Center. We also were able to hear from a past NCI/SITC Immunotherapy Fellowship awardee, doctor and investigator, John Shin, MD, Loma Linda University Health.


Youtube_Image_2116153.png
Click here to view video on YouTube


During our chat, we dug into the microbiome extensively. Dr. Gajewski gave a great overview of what the gut microbiome is and how it can impact the effectiveness of immunotherapy. Dr. Wargo discussed her ground-breaking research on the make-up of the microbiome and how melanoma patients responded to treatment. Next, Dr. Shin discussed a novel decentralized clinical trial he has launched relating to diet and exercise and how it can impact the microbiome and its effect on immunotherapy. Lastly, I had the panel look into the crystal ball to predict how we might intervene in the microbiome in the future to impact the effectiveness of immunotherapy.

I invite you to join our conversation by leaving a comment or question in the video chat. Thank you to my guests Dr. Gajewski, Dr. Wargo and Dr. Shin for their interesting insights into the microbiome and how it can play a role in immunotherapy.


Sincerely,


Patrick Hwu, MD

SITC President

SITC Interim Program: Tumor Immune Microenvironment: A Holistic Approach Hybrid Workshop

Join your colleagues at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment – A Holistic Approach Workshop, April 21-22, 2022 in San Diego, CA, or virtually, that will focus on the tumor microenvironment and its possible impact on the development of future immunotherapies.

Immunotherapeutic approaches are not equally effective across cancer types because not all tumor types are the same. This workshop shines a spotlight on an exciting, emerging area of immunotherapy research. Through this two-day workshop, basic and translational researchers will gain cutting-edge knowledge to different tumor microenvironments and the efficacy of immunotherapy across tumor types, a topic that has largely been unexplored. Plus, SITC members receive a discount off the regular registration rate.

Abstract submissions are now open for the Tumor Immune Microenvironment Workshop! Multiple oral abstract presentation slots will be available and encore presentations are welcome. Abstract submissions are due Monday, Feb. 28 at 5 p.m. PST. To submit an abstract or to learn more about the submission process, click here.

Together, attendees can share research and experiences to ignite a bigger spark for tumor microenvironment investigations and collaborate to improve patient outcomes.
Program Organizers:
Organizers(1)_2116736.png

SITC Members receive a discount on registration fees. Become a member today!


Join SITC in Learning the Latest Advances in Cancer ImmunotherapyTM: A Focus on Intratumoral Therapies, Vaccines, and Cytokines

SITC’s ACI educational programming series is FREE for all healthcare professionals in the clinical setting, students and patient advocates!

Join SITC on Thursday, Jan. 27, 2022 for its live virtual Advances in Cancer ImmunotherapyTM (ACI): A Focus on Intratumoral Therapies, Vaccines, and Cytokines program, hosted on Zoom Webinar. This meeting is part of the newly redesigned Advances in Cancer ImmunotherapyTM (ACI) educational series, with each program offering focused clinical education on a disease state or topic. Attendees of this half-day innovative program will have the opportunity for in-depth education on immunotherapy treatment utilizing intratumoral therapies, vaccines and cytokines from leaders in this specific field. In this meeting, faculty will include education on the latest approvals and treatment recommendations, toxicity management, and biomarkers considerations. The ACI program will also feature a discussion of cases to hear guidance and insights from expert faculty. This meeting is certified for CME, CNE, CPE, and MOC credits.

ACI Program Organizers:
  • Elizabeth Buchbinder, MD – Dana-Farber Cancer Institute
  • Virginia Seery, MSN, RN, ANP, AOCNP – Beth Israel Deaconess Medical Center
  • Ryan J. Sullivan, MD – Massachusetts General Hospital
Register Now

To view all of the ACI available sessions, click here.

    CPGAd_2043736.png